MetaCap

Emmis Acquisition (EMIS) vs Atrium Therapeutics (RNA)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Emmis Acquisition is the larger company by market cap ($163.4 million vs $149.3 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

EMIS+3.03%RNA-53.08%
+16%-22%-60%
Feb 27, 20261 yearNov 20, 2026
EMIS+3.03%RNA-53.08%
+6%-25%-56%
Feb 23, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

EMIS versus RNA key metrics
MetricEMISRNA
Share price$10.36$6.92
Market cap$163.36M$149.27M
1-day change+0.15%-0.86%
YTD return+4.07%—
1-year return+4.39%—
EPS (TTM)—$-5.22
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
52-week high$10.38$16.77
52-week low$9.92$6.36
Distance from 52-week high-0.24%-58.74%
Analyst consensus—strong_buy
Avg. price target upside—+217.92%
Average volume16.19K297.20K
Shares outstanding11.94M21.57M
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Emmis Acquisition

EMIS stock →

Emmis Acquisition Corp. focuses on effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses.

Health Care · Biotechnology: Pharmaceutical Preparations

About Atrium Therapeutics

RNA stock →

Atrium Therapeutics, Inc., a biopharmaceutical company, focuses on delivering ribonucleic acid (RNA) therapeutics to the heart to transform the care for people living with cardiomyopathies. The company's development stage product candidates include ATR 1072, a siRNA-based therapy targeting PRKAG2 for the treatment of PRKAG2 syndrome; and ATR 1086, a siRNA-based therapy targeting PLN for the treatment of PLN cardiomyopathy.

Health Care · Biotechnology: Pharmaceutical Preparations

EMIS vs RNA FAQ

Which is bigger, Emmis Acquisition or Atrium Therapeutics?

Emmis Acquisition (EMIS) is larger, with a market capitalization of $163.36M compared with $149.27M for Atrium Therapeutics (RNA).

Are Emmis Acquisition and Atrium Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons